Prime Therapeutics GLP-1 research: Year-2 cost of care is $4,200 higher for patients with obesity

Real-world study of GLP-1 patients continues to deliver leading insights EAGAN, Minn., Oct. 24, 2024 /PRNewswire/ -- In the latest findings from its industry-leading study, Prime Therapeutics LLC (Prime) announced today that individuals without diabetes who newly started glucagon-like...